Mike R. Lau - Dissemin

All papers authored by Mike R. Lau

This paper was not found in any repository, but could be made available legally by the author.

2023 Christopher P. Vellano, Michael G. White

, Miles C. Andrews

, Manoj Chelvanambi

, Russell G. Witt, Joseph R. Daniele, Mark Titus, Jennifer L. McQuade

, Fabio Conforti, Elizabeth M. Burton, Matthew J. Lastrapes, Gabriel Ologun, Alexandria P. Cogdill

, Golnaz Morad

, Peter Prieto and 50 other authors

Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

2022 Mike R. Lau

Electronic Patient-Reported Outcomes of Adults With BRAF V600–Mutant Stage III-IV Melanoma Treated With Dabrafenib Plus Trametinib Collected Using the Kaiku Health Digital Patient Monitoring Platform

Upload

Mike R. Lau

Predictive role of neutrophil-lymphocyte ratio (NLR) in patients (pts) with metastatic melanoma: A post hoc exploratory analysis from phase 3 COMBI-i trial

Upload

Mike R. Lau

Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of Phase III COMBI-i trial.

Upload

Mike R. Lau

Patient-reported outcomes in patients with resected, stage III BRAF V600E/K-mutant melanoma treated with adjuvant dabrafenib plus trametinib: COMBI-APlus study.

Upload

Mike R. Lau

Updated toxicity profile and relapse-free survival outcomes using an adapted pyrexia management algorithm in patients with resected stage III BRAF V600E/K-mutant melanoma treated with adjuvant dabrafenib plus trametinib in COMBI-APlus

Upload

Eugene Y. Tan, Ovidiu Chiparus, Somesh Choudhury, Christina Kim, Mike Lau

, Christoph Ziltener, Palanichamy Ilankumaran

Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long‐Term Storage at Room Temperature

Upload

This paper is made freely available by the publisher.

Haifeng Zhu, Melinda S. Yates

, Michael G. White

, Christopher P. Vellano, Joseph R. Daniele, Miles Cameron Andrews

, Mark Titus, Fabio Conforti, Russell G. Witt, Manoj Chelvanambi

, Gabriel Ologun, Alexandria P. Cogdill

, Jennifer Leigh McQuade

, Golnaz Morad

, Peter Prieto and 51 other authors

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Download from doi.org

Victoria Atkinson, Caroline Robert, Jean J. Grob

, Helen Gogas, Caroline Dutriaux, Lev Demidov, Avinash Gupta, Alexander M. Menzies, Bettina Ryll, Flora Miranda, Hiya Banerjee, Mike Lau

, Michele Del Vecchio

Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus

Upload

2021 Mike R. Lau

Perspectives on melanoma diagnosis, treatment, and unmet needs as assessed by a social media listening study

Upload

Mike R. Lau

Evaluating patients with a complete response (CR) in the Phase III COMBI-i study of spartalizumab or placebo plus dabrafenib and trametinib (dab + tram) in patients with unresectable or metastatic cutaneous BRAF V600–mutant melanoma

Upload

Mike R. Lau

Concerns of patients with melanoma: gaining insights from social media listening research on symptoms and quality of life

Upload

Mike R. Lau

Real-world outcomes of second-line (2L) dabrafenib plus trametinib in patients with unresectable stage III/IV cutaneous BRAF V600–mutant melanoma

Upload

Mike R. Lau

Regression tree analysis to identify factors associated with relapse-free survival in patients with resected stage III BRAF V600E/K–mutant melanoma.

Upload

Dirk Schadendorf

, Caroline Robert, Reinhard Dummer, Keith T. Flaherty

, Hussein A. Tawbi, Alexander M. Menzies

, Hiya Banerjee, Mike Lau

, Georgina V. Long

Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers

Upload

Victoria Atkinson, Caroline Robert, Alexander M. Menzies, Bettina Ryll, Flora Miranda, Jean-Jacques Grob, Helen Gogas, Caroline Dutriaux, Lev V. Demidov, Avinash Gupta, Hiya Banerjee, Mike R. Lau

, Michele Del Vecchio

Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): primary results of COMBI-APlus.

Download from doi.org

Paolo Antonio Ascierto, Caroline Robert, Paul D. Nathan, Reinhard Dummer, Hussein Abdul-Hassan Tawbi, Keith T. Flaherty, Antoni Ribas, Dirk Schadendorf, Steven Green, Lali Sandalic, Mike R. Lau

, Tonatiuh Romero, Georgina V. Long

Download from doi.org

Mike R. Lau

Pyrexia Real-world characterization of pyrexia in patients with melanoma treated with dabrafenib and trametinib.

Upload

John Kirkwood, Mario Santinami, Vanna Sileni, Marta Nyakas, Reinhard Dummer, Axel Hauschild, Jacob Schachter, Caroline Robert, Victoria Atkinson, Laurent Mortier, James Larkin, Monique Tan, Andrew Haydon, Caroline Dutriaux, Dirk Schadendorf and 5 other authors

Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma

Upload

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

All papers authored by Mike R. Lau